"The next wave of innovation in AI must examine how all the puzzle pieces of human biology are connected..." Aria SVP of R&D Mark G. Eller discussing technology as a new evolution of finding disease. https://t.co/afpS8O3rV2
"That early exploration is the phase where disruptive technology can have a significant impact and bring more potential treatments to the clinic." Read more from Aria SVP of R&D Mark G. Eller discussing technology as the new evolution in fighting diseases.
https://t.co/prtrgQHePl
"In 2022, Aria Pharmaceuticals made significant headway on nearly every front in our mission to bring novel and needed treatments into the clinic." Read more from CEO @andrew_radin as he reflects on Aria's progress in 2022.
https://t.co/KYBnFDORpE
2022 was a year of progress for Aria. CEO @andrew_radin shared his thoughts on this year's accomplishments and looks ahead at 2023 and what's to come. https://t.co/KYBnFE5UrE
We were pleased to have SVP of Nonclinical R&D and Chemistry Anjali Pandey present at the 6th Obesity & NASH Drug Development Summit where she presented on our latest data in #NASH. If you missed the presentation, you can now view it here: https://t.co/dEocs0Bvu8
"I believe it is safe to say that with these traditional lab-based approaches, we have missed potential breakthroughs." Read more from VP Discovery @AaronCDaugherty on how a new approach could help us uncover new promising treatments in @DrugTargetRev
https://t.co/dLMAFQeHeP
Using our Symphony™ AI-platform, @ariapharma has developed a robust pipeline of promising treatments across a range of complex diseases. Learn more about how Symphony™ is purpose-built for biological discovery: https://t.co/Iuehlept2A
Thanks to Pulmonary Fibrosis News for covering our latest findings in our IPF program! Here's a nice roundup of the data Anjali Pandey presented at the Antifibrotic Drug Development Summit in Boston.
https://t.co/ApkYDwrwDt
The 6th Obesity & NASH Drug Development Summit kicks off tomorrow! Don't miss Aria SVP of Nonclinical R&D and Chemistry Anjali Pandey presenting on our latest findings in #NASH.
Don't miss Aria SVP of Nonclinical R&D and Chemistry Anjali Pandey at the 6th Obesity and NASH Drug Development Summit next week where she'll be sharing the latest data from our #NASH program!
https://t.co/GCHMCxKT76
We're please to announce the latest positive results from our IPF program presented at the AFDD Summit! This demonstrates another positive result for our lead TXR-1002 as we move closer to the clinic with a potential treatment for #IPF
https://t.co/velTDZbWLu
We're excited to have SVP Nonclinical R&D and Chemistry Anjali Pandey presenting our latest results in #NASH and #IPF tomorrow at the Antifibrotic Drug Development Summit.
This is biology's century - "Here’s what “biology’s century” means to me: In the same way the 20th century belonged to physics, the 21st is biological." A great piece from @matthewherper
https://t.co/GshFjqPr6y
Following a recent @statnews article from @matthewherper discussing why we're not prepared for the next wave of innovation, our VP Discovery @AaronCDaugherty shared his thoughts on how a shift in mindset can facilitate better results in drug discovery: https://t.co/yR05ECUMaN
It was an honor to have CEO @andrew_radin share the latest from Aria with the @mit_ilp in Seoul at the Startup Showcase and meet with other industry members!
Join Aria SVP of Nonclinical R&D & Chemistry Anjali Pandey at the AFDD Summit Nov 9-11 where she'll be sharing the latest data from our #IPF program along with updates in #NASH. https://t.co/EPfU7UkOVD
Utilizing Symphony™ @ariapharma has developed a pipeline of promising treatments in over a dozen programs across a range of therapeutic areas. Learn more about our pipeline here: https://t.co/dEocs0TEIg